Prevention and Treatment of Prostate Cancer: Technologies and Global Markets

Published - Mar 2017| Analyst - Usha Nagavarapu| Code - PHM113B
Prevention and Treatment of Prostate Cancer: Technologies and Global Markets
Single User License: $2750 Member Price: FREE

Report Highlights

The global market for prostate cancer products reached nearly $47.2 billion in 2016 and should reach nearly $65.1 billion in 2021, with a compound annual growth rate (CAGR) of 6.6%.

Report Includes

  • An overview of the market for the prevention and treatment of prostate cancer, with coverage of the mechanisms of disease development, detection and diagnosis, and anticancer agents
  • Analyses of global market trends, with data from 2012, 2016, and projections of compound annual growth rates (CAGRs) through 2021
  • Discussion of risk factors, natural history, epidemiology, and the genetics of prostate cancer
  • Examinations of prostate-specific antigen (PSA) screening, including the causes of PSA changes, PSA thresholds, and controversies over the screening
  • Coverage of emerging therapies, including combination therapy, therapeutic vaccines, inhibitors of kinase signaling pathways, proteasome inhibitors, angiogenesis inhibitors, and immunotherapeutic agents
  • Evaluation of prostate cancer treatment products by geography, race, and category
  • Breakdown of the industry structure, including market shares, trends in price and price performance, and factors influencing demand
  • Comprehensive company profiles of major players in the field.

Report Scope

The scope of this study is testing, screening technology and also therapeutics markets for prostate cancer. The report also includes the regulatory environment, current technologies, new technologies, prostate cancer incidence, market projections and market share, along with latest trends and new developments.

Screening for diagnosis, therapy via drug, surgery or radiation is measured and broken down by PSA testing, digital rectal exam (DRE), prostate biopsy, hormone therapy, chemotherapy, immunotherapy, external beam radiation therapy (EBRT), prostatectomy and brachytherapy.

Analyst Credentials

Usha Nagavarapu is an experienced pharmaceutical professional with scientific and business development experience. She has managed preclinical discovery programs from target identification, including investigational new drug (IND) enabling studies, and assisted out-licensing and portfolio development activities. Her strong focus areas include oncology, dermatology and cardiovascular diseases. She has extensive experience working with early start-ups to fulfill operational obligations while minimizing overall operational cost and burden.

Table of Contents & Pricing

All reports provided in PDF format. For shared licensing options (5+ Users), please call a representative at (+1) 781-489-7301 or contact us at info@bccresearch.com
Note: Reports are discounted or included with certain Memberships. See Membership Options.
 
Published - Jan-2013| Analyst - Usha Nagavarapu| Code - PHM113A

Report Highlights

The global market for the prevention and treatment of prostate cancer was valued at $26.1 billion in 2011 and should reach nearly $29.3 billion in 2012. Total market value is expected to reach $50.3 billion in 2017 after increasing at a five-year compound annual growth rate (CAGR) of 11.4%.

This report provide:

  • An overview of the market for the prevention and treatment of prostate cancer, with coverage of the mechanisms of disease development, detection and diagnosis, and anticancer agents
  • Analyses of global market trends, with data from 2010, 2011 and 2012, and projections of compound annual growth rates (CAGRs) through 2017
  • Discussion of risk factors, natural history, epidemiology, and the genetics of prostate cancer
  • Examinations of prostate-specific antigen (PSA) screening, including the causes of PSA changes, PSA thresholds, and controversies over the screening
  • Coverage of emerging therapies, including combination therapy, therapeutic vaccines, inhibitors of kinase signaling pathways, proteasome inhibitors, angiogenesis inhibitors, and immunotherapeutic agents
  • Evaluation of prostate cancer treatment products by geography, race, and category
  • Breakdown of the industry structure, including market shares, trends in price and price performance, and factors influencing demand
  • Comprehensive company profiles.

CUSTOM RESEARCH

Need a custom data table, graph or complete report? Tell us more.

Contact Us
RELATED REPORTS
Share This Report